| Product Name |
Recombinant Human Apolipoprotein C1 (APOC1) Protein |
| Product Overview |
This recombinant human Apolipoprotein C1 (APOC1) protein includes amino acids 31-83aa of the target gene is expressed in E.coli.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
P02654 |
| Recommended Name |
Apolipoprotein C-I |
| Gene Name |
APOC1 |
| Synonyms |
Apolipoprotein C-I precursor , APOC1B, Apo-CIB, ApoC-IB, Apolipoprotein C-I, Apolipoprotein C1 |
| Species |
Human |
| Predicted Molecular Mass |
8 kDa |
| Expression System |
E.coli |
| Expression Range |
31-83aa |
| Tag |
N-6His |
| Purity |
>85% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Cardiovascular |
| Target Function |
Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein. |
| Subcellular Location |
Secreted. |
| Protein Family |
Apolipoprotein C1 family |
| Tissue Specificity |
Synthesized mainly in liver and to a minor degree in intestine. Also found in the lung and spleen. |
